press
Whitepaper: A positive prognosis for the future of healthtech
December 16, 2019 + Jessica Di Palo
7 Min read
The healthcare industry is in the midst of a se a change, inspired by the urgent demand for lower cost, higher quality strategies that improve and extend lives. This has, in turn, fostered growing support for a more sustainable healthcare framework, where incentives are oriented toward prevention and quality of care rather than higher volumes and post-diagnosis treatment.
The healthcare industry is in the midst of a sea change, inspired by the urgent demand for lower cost, higher quality strategies that improve and extend lives. This has, in turn, fostered growing support for a more sustainable healthcare framework, where incentives are oriented toward prevention and quality of care rather than higher volumes and post-diagnosis treatment. Further bolstered by an array of economic, demographic and other factors, as well as major technological advances and converging stakeholder interests, the result has been a broad search for digitally-connected, decentralized and patient-centric solutions. With traditional industry players, technology giants, and private equity and other financial operators rushing to join the fray, the healthtech revolution looks to be an investment opportunity-in-the-making.
Share the Article
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
Interview Techtour
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
Interview with Christoph Kausch in biotechandmoney
interview Bioandtechnology
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare
MTIP joins United Nations-supported Principles for Responsible Investments
MTIP signs Principles for Responsible Investments